Home
Solution
Impact
R&D
About
- Team and Board
News and Events
Contact

Month: January 2026

Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-25

Xinnate announces first patient visit has been completed

by Anna-Karin Lindqvist

Recent Posts

5th Öresund Peptide Symposium: 24 September 2026
Xinnate Receives FDA Rare Pediatric Disease Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
debra Care Conference: 26-29 July 2026
Xinnate Appoints Erik Kinnman as Chairman of the Board
Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa

Archives

September 2026
July 2026
June 2026
May 2026
February 2026
January 2026
December 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
January 2025
December 2024
September 2024
May 2024
March 2024
February 2024
March 2023
October 2022
September 2022
July 2022
March 2022
August 2021
October 2020
January 2020

© 2026 Xinnate. All rights reserved